Essentials
• Bleeding is a major source of morbidity during mechanical circulatory support.
• von Willebrand factor (VWF) multimer loss may contribute to bleeding.
• Different patterns of VWF multimer loss were seen with the two device types.
• This is the first report of total artificial heart associated VWF multimer loss.
Summary. Background: Bleeding remains a challenge during mechanical circulatory support and underlying mechanisms are incompletely understood. Functional von Willebrand factor (VWF) impairment because of loss of high-molecular-weight multimers (MWMs) produces acquired von Willebrand disease (VWD) after left ventricular assist device (LVAD). Little is known about VWF multimers with total artificial hearts (TAHs). Here, VWF profiles with LVADs and TAHs are compared using a VWD panel. 
Introduction
An estimated > 5.7 million US adults have heart failure and the incidence of heart failure continues to rise [1] . One-half of patients diagnosed with heart failure are dead within 5 years [2] .Although medical therapy remains the mainstay of heart failure treatment, there is now strong evidence for the addition of additional therapy with mechanical circulatory support devices, which augment or replace the heart's pump function, to improve the survival and quality of life in these patients. The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure, or REMATCH, trial established that mechanical circulatory support with a continuous flow left ventricular assist device (LVAD) significantly improved outcomes for patients with advanced heart failure compared with optimal medical therapy [3] .
In the interim, the number of patients undergoing implantation of support devices has grown considerably. The Interagency Registry for Mechanically Assisted Circulatory Support has reported survival and adverse event data for over 15 000 patients who underwent implantation of durable mechanical circulatory support devices, which include ventricular assist devices and total artificial hearts (TAHs). Over 2500 devices are implanted annually in the USA. In the most recent report, bleeding remained the most frequent adverse event in the first 12 months after implantation, at 7.79 events/100 patient months [4] .
The etiology of bleeding complications after implantation of a support device are thought to be multifactorial. Implicated factors include antiplatelet and anticoagulant therapy intended to reduce the risk of stroke and other thrombotic events, development of angiodysplasias and direct effects of the device on the blood [5] . Changes in von Willebrand factor (VWF) multimers have been identified as an important contribution towards this bleeding diathesis: abnormalities in VWF multimeric profiles are identified in most, if not all, patients supported by continuous flow LVADs [6] [7] [8] and this acquired von Willebrand disease (VWD) appears to resolve after device removal [9] . Mechanoenzymatic degradation of VWF associated with LVADs was first described in 2015 [10] . The loss of high-molecular-weight (HMW) VWF multimers is thought to result from device-dependent higher sheer stress and sheer-stress-driven elevations in ADAMTS-13, a metalloproteinase that cleaves VWF [11, 12] and/or other proteases [13, 14] . Additionally, LVAD-driven shear stress and oxidative stress may increase VWF-platelet binding, which may lead to depletion of HMW VWF multimers [13] . Whether similar changes in VWF multimers that might contribute to bleeding occur during support with TAH remains uninvestigated.
Methods

Patient population
Twenty-four patients with continuous flow LVADS (n = 12) or TAHs (n = 12) hospitalized at Cedars-Sinai Medical Center from 2013 to 2014 underwent VWF multimeric analysis. The indications for performing an acquired VWD evaluation included clinical concern for an acquired bleeding diathesis in the presence of a durable mechanical circulatory support device. International normalized ratio (INR) goals for LVAD patients ranged from 1.5 to 3.5 depending on previous bleeding history and history of thrombosis. INR goals for TAH patients ranged from 2 to 3. Partial thromboplastin time (PTT) goals for both patient populations ranged from 40 to 75 s. This study was approved by the Cedars-Sinai Institutional Review Board. Specimens were collected, processed and stored according to Clinical Laboratory Standards Institute (CLSI) guidelines.
Acquired von Willebrand syndrome evaluation
Acquired VWD panel data were retrospectively reviewed. A ristocetin cofactor (VWF:RCo) assay was performed using the chrono-log agglutination method. Platelet-poor plasma was mixed with the standardized suspension of platelets and ristocetin. Per cent activity was calculated from a standard calibration curve. VWF antigen (VWF: Ag) evaluation was performed by using Diagnostica Stago's Liatest (Diagnostica Stago, Parsippany, NJ, USA), which uses the turbidimetric method. A suspension of latex microparticles coated by covalent bonding with antibodies specific for VWF was mixed with the patient's platelet-poor plasma. Change in turbidity was measured photometrically at 540 nm and converted to per cent of activity by Diagnostica Stago's STA-R Evolution. Factor VIII activity was measured by determining the extent to which the patient's plasma corrects the clotting time of Stago's factor-deficient substrate plasma using Diagnostica Stago's instrumentation and reagents. The per cent activity was determined from a standard curve prepared using serial dilutions of a commercial assayed reference plasma.
VWF quantitative multimeric analysis was performed by the BloodCenter of Wisconsin. In brief, citrated plasma samples underwent LiDS horizontal gel agarose (0.65%) electrophoresis and quantification using immunohistochemistry and densitometry analysis (example cases, calculated based on those boxes and each value is expressed as a percentage of the total. Normal cut-offs and multimer loss criteria were determined by analysis of more than 40 healthy controls and numerous patients and controls with well-defined VWD or healthy profiles. An HMW result of 11-17% is called borderline and represents loss of the highest MW multimers. An HMW result of < 11% represents loss of high MW multimers. An HMW result of 18-34% is called normal. The interpretation of each laboratory result was reviewed by a coagulation pathologist.
Bleeding events
All bleeding events within a 14-day window of the date of VWD evaluation were recorded and characterized by bleeding source (epistaxis, gastrointestinal, mediastinal, retroperitoneal or intracranial) and Bleeding Academic Research Consortium (BARC) criteria, which range from type 0 (no bleeding) to type 5 (fatal bleeding) [15] .
Statistical analysis
All analyses were performed using GraphPad Prism statistical software (GraphPad Software, La Jolla, CA, USA). Continuous variables were summarized using means with standard deviation or medians with interquartile range. Categorical variables were expressed as counts with percentages or ratios. Group comparisons were performed using Fisher's exact tests. Significance was set at a two-sided alpha level of 5%.
Results
Demographic characteristics for the 24 patients included in this study are summarized in Table 1 . Mean patient age was 49.9 AE 16.2 years and 83.3% were male. All patients underwent prior implantation of either continuous flow LVADs (n = 12) or total artificial hearts (n = 12) and at the time of the VWD evaluation the median duration of support was 32 (interquartile range [IQR], 10.3, 56.8) days. Twenty (83.3%) patients were on at least one antithrombotic at the time of VWD evaluation; the remaining four patients all had antithrombotics temporarily withheld because of concern for bleeding. All patients had either normal (47.8%) or elevated (52.2%) ristocetin cofactor (VWF:RCo) and normal (26.1%) or elevated (73.9%) VWF antigen (VWF:Ag) ( Table 2 ). The mean VWF:RCo/VWF:Ag ratio was 0.8 AE 0.3 and one-half of patients had a disproportional ratio. The finding of a reduced ratio of VWF activity (VWF:RCo) in relation to the amount of VWF(VWF:Ag) reflects a relative qualitative VWF defect.
Quantitative VWF multimeric analysis showed abnormal patterns in all 12 patients with LVADs: seven with high MW loss and five with the highest MW multimer loss ( Table S1 .
The incidence of bleeding events within 7 days of VWD evaluation was similar in patients with loss of high MW (4 bleeding events in a total of 2/7 patients) and loss of the highest MW (10 bleeding events in a total of 5/15 patients) multimers (Fisher's exact test, P = 1.0; OR, 0.9 [95% CI, 0.1, 5.6]) (Table 3) . Bleeding events were not explained by supratherapeutic PTT (50.0 AE 15.7 s) or INR (2.0 AE 0.8) levels. There was one bleeding event in the two patients with a normal VWD pattern. The sources of bleeding included epistaxis (n = 6), gastrointestinal bleeding (n = 2), mediastinal bleeding (n = 5) and retroperitoneal bleeding (n = 2). The severity of bleeding events included BARC type II-IV in both groups with the high or highest MW multimer deficits (Table 3) . Four out of seven episodes of severe bleeding (BARC IIIb-IV) were in LVAD patients with high MW multimer deficits.
Discussion
Changes in VWF structure and platelet binding activity associated with LVAD implantation have been well characterized [13, 14] . To date there has been one previous study with a small sample size that has analyzed VWF multimer profiles after implantation of TAH [16] . Heilmann et al. collected VWF multimer profiles in 12 patients, nine with LVADs and three with TAHs, and did not identify changes in VWF activity or loss of HMW multimers. By contrast, using quantitative VWF multimer analysis, we detected abnormalities after LVAD or TAH implantation that would be missed with measurements of VWF level alone. These abnormalities included: a loss of high MWM predominantly in LVAD, a loss of the highest MWM in TAH, and elevated levels of low MWM in both LVAD and TAH. VWF is an acute-phase reactant and levels may be elevated secondary to inflammation and/or infection [17] . The patients in our study had elevated levels of fibrinogen, factor VIII and VWF, which may be driven by an acutephase response. Despite elevated levels of VWF, VWF activity was disproportionately lower, consistent with a relative qualitative defect that may reflect the loss of HMW VWF multimers, which have the greatest hemostatic activity. Whether loss of the highest MW VWF multimers has similar consequences for hemostasis is unknown.
There are emerging data that each mechanical circulatory support device has its own unique hematologic footprint in terms of blood trauma. Different LVAD pumps have different effects on blood physiology, with different frequencies of LDH elevation or fibrin-split products in addition to VWF deficiency, which may be related to variations in flow profiles or pump design [18] . Similarly, when comparing profiles in patients with centrifugal or axial flow pumps, pump factors (type of LVAD and pump speed) and patient factors (age, blood type and CRP) influenced VWF multimer loss [8] . In ex-vivo testing, pumps designed to minimize shear stress appear to cause less VWF degradation [19] .
Strategies to better preserve the HMW VWF during LVAD support have targeted both the enzymatic and mechanical factors that lead to VWF multimer cleavage [14] . Methods to reduce VWF degradation during LVAD support are being studied, including the use of doxycycline to reduce ADAMTS-13 activity [20] and modifications of device speed to limit mechanical sheer stress [8, 19, 21] . Similar studies have not been performed in patients with TAHs.
Limitations
Our study is subject to the limitations inherent to a small, retrospective study, including potential biases in patient selection, variability in the duration of support at the time of VWD evaluation, and the lack of repeated measures of VWD multimers before device implantation and after explantation. Our study neither supports nor refutes a direct causal relationship between the VWF multimeric losses and the incidence of clinically relevant bleeding events. Additionally, there are alternative functional assays for VWF, such as a direct GPIb binding assay or VWF:CB assay, which may better reflect multimer abnormalities than the standard VWF:RCo assay and were not performed in this study.
Conclusion
This is the first study to describe TAH-associated loss of the highest MWM and further investigations into whether the deficit of the highest MW VWF multimers contributes to bleeding are warranted. 
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